Indication
Alzheimer's Disease
The Alzheimer's Disease pipeline: 122 tracked drugs, 5 approved for this indication.
5 approved / phase 413 Phase 310 Phase 2/341 Phase 212 Phase 1/238 Phase 13 preclinical / unstaged
Compare the share prices of listed companies in Alzheimer's Disease →
Total attributable cost
$409.0B
$55,270/patient
Drug spend
$27.0B
$3,650/patient
7% of total cost is drugs
All stages (2026 estimate) · US